Katie Warfel (@ktwarfel) profile picture

Chemical engineer and synthetic biologist | Protein engineering @nablabio | PhD @NUsynbio with @MichaelCJewett

Joined April 2020
Katie Warfel retweeted
Today we’re thrilled to announce JAM-2 — the first AI model capable of generating drug-quality antibodies straight from the computer, with industry-leading success rates. > Drug-like affinities: Picomolar to single-digit nanomolar antibody binders for half of 26 targets while testing <45 designs each. > Unlocking hard targets: Up to 11% success rate for direct on-cell GPCR binders; top antibody hits in the single-digit nanomolar range. > Unprecedented epitope breadth: JAM-2 routinely designed antibodies that hit 30–70% of user-defined epitopes, now enabling intentional design of biology — not chance discovery. > Drug-like developability: Over 50% of antibody designs passed core industry developability criteria with zero optimization. > Massive leverage: A four-person team prosecuted 16 targets in parallel in < 1 month. JAM-2 is the first de novo antibody design capability ready for front-line use in drug discovery, matching or surpassing traditional discovery approaches. We’re already deploying JAM-2 with multiple large pharma partners and seeing excellent results. If you’re interested in partnering on molecule development or accessing JAM-2, contact [email protected]. Read more in our whitepaper (link below)
21
110
41
499
201,910
Today we're announcing a second, larger collaboration with @TakedaPharma — deploying our integrated AI + wet-lab platform broadly across their portfolio to design antibodies, multispecifics, and other next-generation biologics. It’s been incredibly fun working with the Takeda team to create new medicines. Looking forward to doing a lot more of that together.
We’re excited to share a new multi-year collaboration with @TakedaPharma, building on the success of our first engagement. Under the agreement, Nabla will receive double-digit millions in upfront and research payments and is eligible for success-based payments exceeding $1 billion. The partnership deploys Nabla’s AI-driven JAM platform across Takeda’s early-stage programs to include de novo design of antibodies in parallel for multiple targets, multispecifics, challenging targets, and other custom therapeutics. Read more below
24
18
5
185
108,047
Katie Warfel retweeted
We’re excited to share a new multi-year collaboration with @TakedaPharma, building on the success of our first engagement. Under the agreement, Nabla will receive double-digit millions in upfront and research payments and is eligible for success-based payments exceeding $1 billion. The partnership deploys Nabla’s AI-driven JAM platform across Takeda’s early-stage programs to include de novo design of antibodies in parallel for multiple targets, multispecifics, challenging targets, and other custom therapeutics. Read more below
7
21
15
118
107,866
Test-time scaling has arrived for biological design. Excited to share new work from Nabla Bio. By scaling test-time compute, we've achieved remarkable leaps in de novo antibody design against difficult drug targets.
14
94
9
602
60,037
Katie Warfel retweeted
Alli will be giving a talk about some of our latest results on antibody design for GPCRs, and the protein production and characterization challenges that go along with that at PEGS Boston 9AM Monday.
3
1
8
1,479
If you're at BioLogic in San Diego next week, check out Adithya's talk on our work in de novo antibody design!
5
7
894
Katie Warfel retweeted
Our own Adithya Paramasivam will be giving a talk on our work in de novo antibody design at the BioLogic Summit in San Diego next week. Looks like it will be a great event!
3
5
534
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function. We’re seeing success across a range of soluble and hard-to-drug membrane proteins including a Claudin and a GPCR. We’ve extensively tested these designs in our wet lab and included detailed data and controls, providing the first clear demonstration of how de novo design could expand the scope and efficiency of therapeutic antibody discovery. 🧵 Technical report: nabla-public.s3.us-east-1.am… Blog: nabla.bio/news/denovo
12
60
10
234
53,771
Katie Warfel retweeted
Excited to announce that I will be joining @NorthwesternEng and @nu_chbe as an Assistant Professor in Jan 2025! We work at the intersection of synthetic biology and process engineering toward a bio-enabled, sustainable future. Let's discover together! #synbio #newPI @NUSynBio
26
13
6
142
14,924
I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.
5
26
2
83
17,490
Excited to share @nablabio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add @radicalvcfund who led our $26M Series A to the family! bit.ly/4dDk4lP
12
41
12
114
53,097
Let's say you want to make a glycoprotein. How would you do it? How could you do it for decentralized manufacturing? Cell-free systems offer a path. Check out our @NatureProtocols paper. @JessicaCStark @DeLisaGroup @mattdelisa @ktwarfel @jasminehershewe nature.com/articles/s41596-0…
26
1
115
9,889
New vaccine candidates could be developed more quickly with a novel immune cell testing platform. fal.cn/3xQy0 #Chemistry #Research #Vaccine #Cell #DrugDevelopment @ACSCentSci @ACSPublications
5
2
19
8,982
Another step toward developing more affordable & accessible vaccines against enteric infections! Out today, our latest research describes the protective efficacy & immunogenicity in 🐭 of our ETEC vaccine candidates, produced via biosynthetic routes. frontiersin.org/articles/10.…
7
16
2,819
A collaborative effort with @ktwarfel⁩ ⁦@primitdesai⁩ ⁦@MichaelCJewett⁩ ⁦@mattdelisa⁩ & others - glad this story on our enteric vaccine candidates is finally out! Also grateful for useful feedback from thoughtful reviewers. frontiersin.org/articles/10.…
2
6
21
3,284
Do you like video games? community science? ribosomes? Meet community science designed ribosomes @NatureComms. @RDasLab @NUSynBio @StanfordBioE @amw_stanford @AntyeKruger @eternagame discover mutant ribosomes that improve protein synthesis. Such a fun collaboration👇 #synbio
1
29
107
14,938
How can we make medicines for deployment in resource-limited settings that current economics simply do not allow? Might cell-free #synbio systems help? @GENbio highlights our new @ACSSynBio work exploring this question @ktwarfel @DeLisaGroup @StanfordBioE genengnews.com/topics/drug-d…
4
23
4,592